Roche is the recipient of the new approval, getting the go-ahead from the US regulator for its PATHWAY HER2 (4B5) test to ...

The new second-line indication was approved by the FDA in May, leading analysts at Jefferies to predict that it could add $500 million in worldwide peak sales for Enhertu and start to unlock ...

Enhertu has been a major commercial success for AstraZeneca and Daiichi Sankyo, generating $3bn in revenue in 2023, as per the company financials. According to GlobalData’s Pharma Intelligence Center, ...

The Food and Drug Administration on Monday expanded use of AstraZeneca and Daiichi Sankyo’s Enhertu, allowing the drug to be given earlier and more broadly in people with an aggressive form of breast ...

According to GlobalData’s Pharma Intelligence Center, the drug is projected to reach $13.9bn in sales by 2030. GlobalData is the parent company of Pharmaceutical Technology. Despite Enhertu’s ...

Daiichi Sankyo recognizes Enhertu sales in the U.S. AstraZeneca reports its share of gross profit margin from Enhertu sales in the U.S. as Alliance Revenue in the company’s financial statements.

Enhertu (fam-trastuzumab deruxtecan-nxki) can cause side effects that range from mild to serious. More common side effects include hair loss, nausea, and vomiting. If Enhertu side effects become ...

Sales of Enhertu in the US are recognised by Daiichi Sankyo. AstraZeneca reports its share of gross profit margin from Enhertu sales in the US as Alliance Revenue in the Company’s financial statements ...